KRAS Mutations Match in Almost All Tumors

If there is a KRAS mutation in the primary colon or rectal tumor, there is almost always a matching mutation when that tumor spreads to the liver. Researchers in the Netherlands tested both tumors for KRAS mutations in over 300 patients whose cancer had spread to their livers. They found about a third of patients had…  Read More

Mutations are Not All the Same

We are making significant progress in understanding what genetic alterations in tumors really mean. Over the last two years, we have learned or the first time that there is an alteration in a gene called KRAS in colon cancer, and tumors which have this mutation do not respond to treatment with Erbitux® (cetuximab) or Vectibix® (panitumumab).…  Read More

Adding Erbitux to First Line Chemotherapy Helps Advanced Colorectal Cancer Patients with Wild Type KRAS

Does adding Erbitux to chemotherapy help people whose colorectal cancer has spread beyond the colon or rectum to distant body sites? The answer is yes, according to a pooled analysis of two large randomized clinical trials comparing chemotherapy alone to chemotherapy plus Erbitux® (cetuximab).  However, benefits depend on whether or not patient tumors have mutations of…  Read More